Cerus Corporation Announces CMS Issuance of P-Codes for Hospital Outpatient Billing of INTERCEPT-Based Therapeutic ProductsBusiness Wire • 08/10/21
Cerus Corporation (CERS) CEO Obi Greenman on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 08/04/21
Cerus Corporation Announces Record Second Quarter 2021 Financial Results and Raises Full Year Product Revenue GuidanceBusiness Wire • 08/03/21
Cerus Corporation Announces CMS Has Granted New Technology Add-On Payment for INTERCEPT Fibrinogen ComplexBusiness Wire • 08/03/21
Cerus Corporation to Release Second Quarter 2021 Financial Results on August 3, 2021Business Wire • 07/20/21
Cerus Corporation and the Swiss Red Cross Celebrate 10 Years of Routine Use of INTERCEPT Blood System for PlateletsBusiness Wire • 07/14/21
Cerus Announces Collaboration with LifeSouth Community Blood Centers to Manufacture INTERCEPT® Fibrinogen ComplexBusiness Wire • 06/30/21
Cerus Corporation Announces Contract with Canadian Blood Services for INTERCEPT Blood System for PlateletsBusiness Wire • 05/17/21
Cerus Corporation (CERS) CEO Obi Greenman on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/05/21
Cerus Corporation Announces First Quarter 2021 Financial Results and Raises Full Year Product Revenue GuidanceBusiness Wire • 05/04/21
Cerus Corporation to Release First Quarter 2021 Financial Results on May 4, 2021Business Wire • 04/20/21
Cerus Corporation's (CERS) CEO Obi Greenman on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha • 02/26/21
Cerus Corporation Announces Record Fourth Quarter and Full Year 2020 Financial ResultsBusiness Wire • 02/25/21
Cerus Corporation and Shandong Zhongbaokang Medical Implements Partner to Establish Joint Venture in ChinaBusiness Wire • 02/24/21